Umecrine Cognition Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.54M
- Investors
-
8
Umecrine Cognition General Information
Description
Developer of pharmaceutical drugs designed to treat cognitive neurological disorders. The company offers drugs for the treatment of symptoms in the central nervous system related to chronic neuroinflammation, a brain distortion that can lead to severely impaired cognition and fatigue, enabling healthcare industries to directly address the neurocognitive signs and symptoms of hepatic encephalopathy.
Contact Information
Website
www.umecrinecognition.comCorporate Office
- Karolinska Institutet Science Park
- Nanna Svartz väg 6A
- 171 65 Solna
- Sweden
Corporate Office
- Karolinska Institutet Science Park
- Nanna Svartz väg 6A
- 171 65 Solna
- Sweden
Umecrine Cognition Timeline
Umecrine Cognition Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 14-Jul-2025 | $5.54M | Completed | Clinical Trials - Phase 2 | ||
| 9. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 8. Later Stage VC | 17-Nov-2023 | Completed | Clinical Trials - Phase 2 | |||
| 7. Debt - General | 28-Mar-2023 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 14-Sep-2022 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | 14-Jul-2021 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 31-Dec-2019 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 04-Oct-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC | 22-Nov-2016 | $4.96M | $5.4M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC | 31-Dec-2011 | $438K | $438K | Completed | Startup |
Umecrine Cognition Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Preference | 199,950 | $18.71 | $18.71 | 1x | $18.71 | 39.59% | ||
| Preference | 20,833 | $16.84 | $16.84 | 1x | $16.84 | 4.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Umecrine Cognition Comparisons
Industry
Financing
Details
Umecrine Cognition Competitors (3)
One of Umecrine Cognition’s 3 competitors is Dilafor, a Venture Capital-Backed company based in Solna, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dilafor | Venture Capital-Backed | Solna, Sweden | ||||
| AlzeCure Pharma | Corporate Backed or Acquired | Huddinge, Sweden | ||||
| Scandinavian Biopharma | Venture Capital-Backed | Solna, Sweden |
Umecrine Cognition Patents
Umecrine Cognition Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025252724-A1 | Novel pharmaceutical formulation of golexanolone | Pending | 04-Jun-2024 | ||
| WO-2025252725-A1 | Novel pharmaceutical formulation of golexanolone | Pending | 04-Jun-2024 | ||
| EP-4389129-A1 | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia | Inactive | 22-Dec-2022 | ||
| US-20260207625-A1 | New medical use of 3a-ethynyl-3ß hydroxyandrostan-17-one oxime | Pending | 22-Dec-2022 | ||
| EP-4637782-A1 | New medical use of 3alpha-ethynyl-3beta hydroxyandrostan 17-one oxime | Pending | 22-Dec-2022 | A61K31/568 |
Umecrine Cognition Signals
Umecrine Cognition Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ribbskottet | Corporation | |||
| AB Ility | Venture Capital | Minority | ||
| Almi Invest | Venture Capital | Minority | ||
| Fort Knox | Family Office | Minority | ||
| KDventures | Venture Capital | Minority |
Umecrine Cognition FAQs
-
When was Umecrine Cognition founded?
Umecrine Cognition was founded in 2006.
-
Where is Umecrine Cognition headquartered?
Umecrine Cognition is headquartered in Solna, Sweden.
-
What is the size of Umecrine Cognition?
Umecrine Cognition has 1 total employees.
-
What industry is Umecrine Cognition in?
Umecrine Cognition’s primary industry is Drug Discovery.
-
Is Umecrine Cognition a private or public company?
Umecrine Cognition is a Private company.
-
What is Umecrine Cognition’s current revenue?
The current revenue for Umecrine Cognition is .
-
How much funding has Umecrine Cognition raised over time?
Umecrine Cognition has raised $28.2M.
-
Who are Umecrine Cognition’s investors?
Ribbskottet, AB Ility, Almi Invest, Fort Knox, and KDventures are 5 of 8 investors who have invested in Umecrine Cognition.
-
Who are Umecrine Cognition’s competitors?
Dilafor, AlzeCure Pharma, and Scandinavian Biopharma are competitors of Umecrine Cognition.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process